CN110063374B - Composite probiotic composition for improving breath, buccal tablet and preparation method thereof - Google Patents
Composite probiotic composition for improving breath, buccal tablet and preparation method thereof Download PDFInfo
- Publication number
- CN110063374B CN110063374B CN201910453030.0A CN201910453030A CN110063374B CN 110063374 B CN110063374 B CN 110063374B CN 201910453030 A CN201910453030 A CN 201910453030A CN 110063374 B CN110063374 B CN 110063374B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- composite probiotic
- lactobacillus plantarum
- probiotic composition
- buccal tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 92
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 92
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 84
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 229940046011 buccal tablet Drugs 0.000 title claims abstract description 30
- 239000002131 composite material Substances 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 48
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 48
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 48
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 28
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 24
- 238000004321 preservation Methods 0.000 claims description 20
- 239000002207 metabolite Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 235000010469 Glycine max Nutrition 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 244000068988 Glycine max Species 0.000 claims description 9
- 235000013312 flour Nutrition 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 235000021552 granulated sugar Nutrition 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims 1
- 150000001746 carotenes Chemical class 0.000 claims 1
- 235000005473 carotenes Nutrition 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 235000020183 skimmed milk Nutrition 0.000 claims 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 abstract description 20
- 206010006326 Breath odour Diseases 0.000 abstract description 17
- 208000032139 Halitosis Diseases 0.000 abstract description 17
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract description 6
- 150000003464 sulfur compounds Chemical class 0.000 abstract description 5
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 abstract description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 1
- 108010062877 Bacteriocins Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000010794 food waste Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000020255 yak milk Nutrition 0.000 description 2
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/18—Milk in dried and compressed or semi-solid form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Abstract
The application provides a compound probiotic composition for improving halitosis and contain compound probiotic buccal tablet of compound probiotic composition, probiotic composition and compound probiotic buccal tablet are formed by compounding a plurality of probiotics, probiotic composition can restrain the multiplication of pathogenic bacteria in the oral cavity, remove volatile sulfur compounds such as methyl mercaptan, hydrogen sulfide and the like which cause halitosis, adjust immunity, treat allergy, maintain oral health, thereby fundamentally solving the problems of halitosis and the like.
Description
Technical Field
The invention relates to the technical field of health-care food, and particularly relates to a composite probiotic composition for improving halitosis, a buccal tablet, a preparation method and application.
Background
Halitosis is one of the common oral diseases in clinic, is a sensitive problem which troubles patients and brings adverse effects to social interaction of the patients. Causes of halitosis are roughly divided into oral local factors and systemic factors, wherein the oral local factors cause halitosis accounting for more than 85% of the whole population, and oral micro-ecological disorder in the oral local factors is one of the causes of halitosis. Specifically, food residues in the oral cavity adhere to the back of the tongue, and microorganisms in the oral cavity decompose the protein, blood, mucin, and other components in the food residues, and if the oral cavity micro-ecology is normal, the decomposition products are odorless, but if the oral cavity micro-ecology is disordered, products having an offensive odor, such as volatile sulfides such as methyl mercaptan, hydrogen sulfide, and the like, in the decomposition products are increased, thereby causing halitosis.
In the prior art, the method for adjusting the oral cavity micro-ecology comprises the use of products such as toothpaste, mouthwash and the like, and the principle is that all microorganisms in the oral cavity are eliminated, the oral cavity is thoroughly cleaned, the oral cavity micro-ecology is not adjusted, and the method cannot effectively improve the ozostomia for organisms with the oral cavity micro-ecology being disordered.
Disclosure of Invention
The invention provides a composite probiotic composition for improving halitosis and a composite probiotic buccal tablet containing the composite probiotic composition, wherein the probiotic composition and the composite probiotic buccal tablet are compounded by a plurality of probiotics, and the probiotic composition can inhibit the proliferation of pathogenic bacteria in oral cavity, remove volatile sulfur compounds such as methyl mercaptan, hydrogen sulfide and the like which cause halitosis, regulate immunity, treat allergy and maintain oral health, thereby fundamentally solving the problems of halitosis and the like.
The present application aims to provide the following aspects:
in a first aspect, the present application provides a composite probiotic composition for improving breath, comprising Lactobacillus paracasei Z6(Lactobacillus paracasei Z6), Lactobacillus plantarum Lp-6(Lactobacillus plantarum Lp-6), Lactobacillus plantarum P9(Lactobacillus plantarum P9), and Lactobacillus rhamnosus M9(Lactobacillus rhamnosus M9).
In the application, the Lactobacillus paracasei Z6(Lactobacillus paracasei Z6) is separated from the sour yak milk of the Dangxiang county in the Tibetan Lassa, the collected sour yak milk is finally separated to obtain a Lactobacillus paracasei Z6(Lactobacillus paracasei Z6) capable of adjusting the oral microecological balance through disinfection, inoculation, separation, purification and identification, the strain is submitted to a patent approved organization for preservation, the preservation time is 3 months and 18 days in 2019, the microorganism preservation number is CGMCC No.17342, the Lactobacillus paracasei is classified and named as Lactobacillus paracasei, the preservation unit is the China Committee for culture Collection of microorganisms, the Beijing institute of culture Collection, North American society for culture Collection, No. 3 of Western No.1, and the institute of microbiology, China institute of sciences.
The Lactobacillus plantarum Lp-6(Lactobacillus plantarum Lp-6) is preserved in a patent approved organization, the preservation time is 2018, 10 months and 31 days, the microorganism preservation number is CGMCC No.16661, the Lactobacillus plantarum is named by classification, the preservation unit is China general microbiological culture Collection center (CCCCCCC), the preservation address is No. 3 of Xilu No.1 of the sunward district of Beijing, China institute of sciences and microbiology.
The Lactobacillus plantarum P9(Lactobacillus plantarum P9) is preserved in a patent approved organization, the preservation time is 2018, 10 and 31 days, the microorganism preservation number is CGMCC No.16662, the Lactobacillus plantarum is named by classification, the preservation unit is the China general microorganism culture Collection of the Committee for culture Collection of microorganisms, the preservation address is No. 3 of Xilu No.1 of the sunward district of Beijing, China institute of sciences, China.
The Lactobacillus rhamnosus M9(Lactobacillus rhamnous M9) is preserved in a patent approved organization, the preservation time is 22 days 6 months 6 years 2018, the microorganism preservation number is CGMCC No.16002, the Lactobacillus rhamnosus is named as Lactobacillus rhamnosus by classification, the preservation unit is the general microorganism culture preservation center of China Committee for culture Collection of microorganisms, the preservation address is No. 3 of Western Lu No.1 of the sunward district, Beijing, China institute of sciences and microbiology.
In one achievable form, the weight ratio of lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9, and lactobacillus rhamnosus M9 in the composite probiotic composition is lactobacillus paracasei Z6: lactobacillus plantarum Lp-6: lactobacillus plantarum P9: lactobacillus rhamnosus M9 ═ 2-4: 3-4: 2-6: 1-5.
In the present application, the viable count of each strain in the composite probiotic composition is respectively as follows based on the total weight of the composite probiotic composition:
in one achievable mode, in the complex probiotic composition, the lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 are bacterial powders, respectively.
In a second aspect, the application also provides a composite probiotic buccal tablet, which comprises the composite probiotic composition.
Optionally, the composite probiotic buccal tablet further comprises metabolites of the lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9.
Furthermore, the compound probiotic buccal tablet comprises the following components in parts by weight:
wherein 1g is 1 part by weight.
In one implementable form, the prebiotic comprises one or more of inulin, galacto-oligosaccharide, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide and/or soy oligosaccharide.
In one realizable approach, the excipients include one or more of microcrystalline cellulose and/or magnesium stearate.
In one achievable form, the excipient comprises the following components in parts by weight, based on the total weight of the excipient:
5-18 parts of microcrystalline cellulose;
0.1-2 parts of magnesium stearate.
In one realizable approach, the binder includes one or more of absolute ethanol, 5% PVP ethanol solution, and/or 5% starch syrup.
In a third aspect, the present application also provides a method for preparing the complex probiotic metabolite, the method comprising the steps of:
step 1-1: adding defatted soybean flour and yeast powder into preheated distilled water, hydrating, sterilizing, and cooling to normal temperature to obtain raw material liquid;
step 1-2: inoculating lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 into the raw material liquid for fermentation, and obtaining a probiotic lactobacillus metabolite base material after the fermentation end point is reached;
step 1-3: and (3) mixing the metabolite base material obtained by fermentation in the step (1-2) with a carrier, and carrying out spray drying to obtain the composite probiotic metabolite.
In one possible implementation manner, in step 1-1, the defatted soybean flour and yeast powder can be defatted soybean flour and yeast powder commonly used in the art; the temperature of the preheated distilled water may be 45-65 ℃, for example, 55 ℃, so as to dissolve the defatted soybean flour; the hydration means to dissolve the defatted soy flour sufficiently.
Further, in step 1-2, the content of Lactobacillus paracasei Z6 inoculated in the raw material liquid is 1X 104-5×106CFU/g, the content of Lactobacillus plantarum Lp-6 is 1 multiplied by 104-5×106CFU/g, the content of Lactobacillus plantarum P9 is 1 × 104-5×106CFU/g, and the content of Lactobacillus rhamnosus M9 is 1 × 104-5×106CFU/g; the fermentation temperature is 35-45 ℃, and the acidity at the fermentation end point is 100-200 DEG T.
Further, in steps 1-3, the spray drying method may be any method of spray drying the metabolites of the probiotic bacteria according to the prior art.
Alternatively, the carrier may be maltodextrin, further the metabolite base to carrier weight ratio may be (5-9): (2-4), for example 7: 3.
In a fourth aspect, the present application also provides a method for preparing the aforementioned composite probiotic buccal tablet, which comprises the following steps:
step 2-1, batching: pulverizing all the components, sieving respectively, and mixing the raw materials except excipient, composite probiotic powder and adhesive in proportion;
step 2-2, granulating: uniformly spraying a binder into the raw materials, uniformly wetting the raw materials obtained by mixing in the step 1 to obtain a soft material, sieving the soft material with a 18-mesh sieve for granulation, drying the granulated material in an oven at a low temperature, crushing the granulated material after the water activity is less than or equal to 0.2wt% and the water content is less than 5wt%, and sieving the crushed material with a 16-mesh sieve for size stabilization;
step 2-3, tabletting: and (3) adding the composite probiotic powder and an excipient into the dried particles prepared in the step (2-2), uniformly mixing, standing for 20-50min, and tabletting to obtain the composite probiotic buccal tablet.
In one possible implementation, in step 2-1, the sieving may be through an 80-mesh sieve, and the drying temperature is 10-30 ℃.
Optionally, the hardness range of the composite probiotic buccal tablet is 10-20 kg.
In a fifth aspect, the present application also provides the use of the complex probiotic composition as an oral cleanser.
In a sixth aspect, the application also provides the use of the composite probiotic buccal tablet as an oral cavity cleaning agent.
Compared with the prior art, the compound probiotic buccal tablet with the function of improving breath comprises 4 probiotics such as lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 and a compound probiotic metabolite produced by four probiotics through fermenting defatted soybean meal, wherein the 4 probiotics have synergistic effect in the process of fermenting defatted soybean meal and can generate a plurality of organic acids, antibacterial peptides, bacteriocins and short-chain fatty acids, for example, bioactive substances such as phenyllactic acid, 4-hydroxy phenyllactic acid, antibacterial peptides and bacteriocins, the bioactive substances have broad-spectrum antibacterial property, have natural bacteriostatic activity and strong killing effect on bacteria, and the generating bacteria have autoimmunity on the bacteriocins, namely, the probiotics can generate the bacteriocins in the fermentation process and the bacteriocins can inhibit the growth of pathogenic bacteria, but has no inhibition effect on probiotics per se and can treat various oral pathogenic bacteria, such as: the streptococcus mutans, the porphyromonas gingivalis, the bacteria of Fossilia and the like have an inhibiting effect, so that the composite probiotic buccal tablet provided by the application has the effects of regulating the oral flora balance, inhibiting dental caries bacteria and periodontal pathogenic bacteria, removing volatile sulfur compounds causing halitosis, improving the oral microenvironment on the whole, cleaning the oral cavity and improving the breath, and provides a new direction for preventing or treating oral diseases.
The applicant also finds that the composite probiotic buccal tablet provided by the application has a regulating effect on oral micro-ecological environment, can influence the change of humoral immune cells, enhances the immune function, can compete with oral pathogenic bacteria on binding sites of epithelial cells, oral mucosa or tooth surfaces, and reduces the self adhesion of pathogenic bacteria, and in addition, when the probiotic bacteria are fused behind the oral microbial flora, extracellular polysaccharide can be generated, and a biofilm is formed in the oral environment by virtue of the strong aggregation capability of the probiotic bacteria, so that the growth of the oral pathogenic microorganisms is inhibited.
Detailed Description
The present invention is explained below with reference to examples, which are merely illustrative of the present invention. Unless otherwise specified, the technical means used in the present invention are well known to those skilled in the art. In addition, the embodiments should be considered illustrative, and not restrictive, of the scope of the invention, which is defined solely by the claims. It will be apparent to those skilled in the art that various changes or modifications in the components and amounts of the materials used in these embodiments can be made without departing from the spirit and scope of the invention.
The strains used in the examples of the present application are provided in the key laboratory of the department of education "dairy biotechnology and engineering" of the university of inner Mongolia agriculture.
Examples
Example 1-example 3: preparation of composite probiotic buccal tablet
Preparation of composite probiotic metabolite
Step 1-1: adding defatted soybean flour, white sugar and yeast powder into distilled water preheated to 55 deg.C, stirring, dissolving sufficiently, hydrating for 40min, heating to 90 deg.C, maintaining the temperature for 10min, sterilizing, and cooling to 38 deg.C to obtain raw material liquid;
step 1-2: and (2) inoculating lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 into the raw material liquid prepared in the step (1-1), and fermenting at 40 ℃ until the fermentation end point reaches 150 degrees T to obtain the high-concentration probiotic lactobacillus metabolite.
Step 1-3: and mixing 700g of the metabolite obtained by fermentation with 300g of carrier maltodextrin, and performing spray drying to obtain the composite probiotic metabolite.
(II) preparing the compound probiotic buccal tablet (wet granulation and tabletting method):
(1) preparing materials: pulverizing all the ingredients, respectively sieving with 80 mesh sieve, and mixing the raw materials except excipient, composite probiotic powder and adhesive (5% PVP ethanol solution) at the above ratio;
(2) and (3) granulating: uniformly spraying a proper amount of 5% PVP ethanol solution into the raw materials to uniformly wet the raw materials, preparing a soft material, sieving with a 18-mesh sieve for granulation, drying in a 15-DEG C oven, crushing after the water activity is less than or equal to 0.2% and the water content is less than 5%, and sieving with a 16-mesh sieve for size stabilization;
(3) tabletting: adding composite probiotic powder and excipient into the dried granules, mixing, standing for 20-50min, and tabletting to obtain composite probiotic buccal tablet with specification of 0.5-2g and hardness range of 10-20 kg.
TABLE 1 proportions of the components of the examples
In table 1, in the composite probiotic powder, the weight ratio of lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 is lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9, lactobacillus rhamnosus M9-20: 20:20: 40.
In table 1, the weight ratio of defatted soybean flour, white granulated sugar, yeast powder and water in the composite probiotic metabolite is 60:60:10: 870.
Further, the composite probiotic metabolite is fermented by the following fermentation strains: based on the weight of the defatted soybean flour, 2000 hundred million CFU/g of Lactobacillus paracasei Z6, 2000 hundred million CFU/g of Lactobacillus plantarum Lp-6, 2000 hundred million CFU/g of Lactobacillus plantarum P9, and 4000 hundred million CFU/g of Lactobacillus rhamnosus M9.
Example 4 Compound probiotic buccal tablets in human tests for the removal of halitosis
1. Volunteers: 80 patients, 20-45 years old, all had subjective or objective symptoms of halitosis.
2. Grouping:
(1) control group (group a): 0.85% of normal saline, wherein n is 20;
(2) probiotic buccal tablets (group B): adding 1.0% of the probiotic buccal tablet in the example 1, dissolving in normal saline, wherein n is 20;
(3) probiotic buccal tablets (group C): adding 1.0% of the probiotic buccal tablet in the example 2, dissolving in normal saline, wherein n is 20;
(4) probiotic buccal tablets (group D): the probiotic buccal tablet of example 2 was dissolved in normal saline with the addition of 1.0%, n-20.
In this example, the selected volunteers had less variation in the degree of halitosis, and therefore, the mass concentration of volatile sulfur compounds in the oral cavity before the volunteers rinsed their mouths in Table 2 was averaged for all volunteers.
3. The test method comprises the following steps:
the gargling time is 3min, and the detection is carried out before gargling and after gargling respectively.
The concentration of VSCs of volatile sulfur compounds in the oral cavity of volunteers was measured by a portable gas chromatograph OralChroma and the results are shown in table 2:
TABLE 2 volunteer oral cavity volatile sulfide concentration Change (. mu.g/L)
As shown in table 2, the difference in the total mass concentration of 3 gases in the oral cavity after the mouth is rinsed with the tablet containing complex probiotics has a significant meaning compared with the control group (F is 20.395, P is less than 0.01).
Specifically, the main component H of volatile sulfide can be treated by using group C or group D compound probiotic buccal tablet2S、CH3The SH removing effect is most obvious (F is 9.043, P)<0.01)。
Therefore, the composite probiotic buccal tablet can effectively reduce the H causing halitosis2S、CH3Volatile sulfides such as SH, etc., and has effects of cleaning oral cavity and improving halitosis.
For group B, the ability to degrade sulfides was lower compared to groups C and D.
The present application has been described in detail with reference to specific embodiments and illustrative examples, but the description is not intended to limit the application. Those skilled in the art will appreciate that various equivalent substitutions, modifications or improvements may be made to the presently disclosed embodiments and implementations thereof without departing from the spirit and scope of the present disclosure, and these fall within the scope of the present disclosure. The protection scope of this application is subject to the appended claims.
Claims (10)
1. A composite probiotic composition for improving breath is characterized in that the composite probiotic composition is prepared from lactobacillus paracasei (Lactobacillus paracasei)Lactobacillus paracasei) Z6 Lactobacillus plantarum (L.)Lactobacillus plantarum) Lp-6, Lactobacillus plantarum (L)Lactobacillus plantarum) P9 and Lactobacillus rhamnosus (L.) (Lactobacillus rhamnosus) M9, wherein the microorganism preservation number of the lactobacillus paracasei Z6 is CGMCC number 17342, the microorganism preservation number of the lactobacillus plantarum Lp-6 is CGMCC number 16661, the microorganism preservation number of the lactobacillus plantarum P9 is CGMCC number 16662, and the microorganism preservation number of the lactobacillus rhamnosus M9 is CGMCC number 16002.
2. The composite probiotic composition according to claim 1, wherein the weight ratio of lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9, and lactobacillus rhamnosus M9 in the composite probiotic composition is lactobacillus paracasei Z6: lactobacillus plantarum Lp-6: lactobacillus plantarum P9: lactobacillus rhamnosus M9= (2-4): (3-4): (2-6): (1-5).
3. The composite probiotic composition according to claim 1 or 2, wherein the viable count of each strain in the composite probiotic composition is respectively:
lactobacillus paracasei Z62000-3000 hundred million CFU/g;
lactobacillus plantarum Lp-62000-4000 billion CFU/g;
lactobacillus plantarum P92000-4000 hundred million CFU/g;
lactobacillus rhamnosus M94000-5000 hundred million CFU/g.
4. The composite probiotic composition according to claim 1 or 2, characterized in that in the composite probiotic composition, the lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 are bacterial powders.
5. A composite probiotic buccal tablet, which is characterized by comprising the composite probiotic composition according to any one of claims 1 to 4.
6. The compound probiotic buccal tablet according to claim 5, characterized by comprising the following components in parts by weight:
20-30 parts of skim milk powder;
5-15 parts of the composite probiotic composition of any one of claims 1 to 4;
15-40 parts of composite probiotic metabolites;
20-40 parts of prebiotics;
5-20 parts of an excipient;
0.01-1 part of carotene;
0.1-0.3 part of citric acid;
0.1 to 1 portion of adhesive,
wherein 1 part by weight of 1g,
wherein the complex probiotic metabolite is prepared by a method comprising the following steps:
step 1-1: adding defatted soybean flour, white granulated sugar and yeast powder into preheated distilled water, hydrating, sterilizing and cooling to obtain a raw material liquid;
step 1-2: inoculating lactobacillus paracasei Z6, lactobacillus plantarum Lp-6, lactobacillus plantarum P9 and lactobacillus rhamnosus M9 into the raw material liquid for fermentation, and obtaining a probiotic lactobacillus metabolite base material after the fermentation end point is reached;
step 1-3: and (3) mixing the metabolite base material obtained by fermentation in the step (1-2) with a carrier, and carrying out spray drying to obtain the composite probiotic metabolite.
7. The composite probiotic buccal tablet according to claim 6, characterized in that,
the prebiotics are one or more of inulin, galacto-oligosaccharide, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide and/or soybean oligosaccharide; and/or
The excipient is one or more of microcrystalline cellulose and/or magnesium stearate; and/or
The adhesive is one or more of absolute ethyl alcohol, 5% PVP ethanol solution and/or 5% starch syrup.
8. A method for preparing the composite probiotic buccal tablet according to any one of claims 5 to 7, characterized in that the method comprises the following steps:
step 2-1, batching: pulverizing all the components, sieving respectively, and mixing the raw materials except excipient, composite probiotic composition powder and adhesive in proportion;
step 2-2, granulating: uniformly spraying a binder into the raw materials, uniformly wetting the raw materials mixed in the step 2-1 to prepare a soft material, sieving and granulating the soft material, drying the soft material in an oven at a low temperature after granulation, crushing the soft material after the water activity is less than or equal to 0.2wt% and the water content is less than 5wt%, and sieving and grading the soft material;
step 2-3, tabletting: and (3) adding the composite probiotic composition bacterium powder and an excipient into the dried particles prepared in the step 2-2, uniformly mixing, standing and tabletting to obtain the composite probiotic buccal tablet.
9. Use of the complex probiotic composition of any one of claims 1 to 4 for the preparation of an oral cleanser.
10. Use of the composite probiotic buccal tablet of any one of claims 5 to 7 for preparing an oral cleanser.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910453030.0A CN110063374B (en) | 2019-05-28 | 2019-05-28 | Composite probiotic composition for improving breath, buccal tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910453030.0A CN110063374B (en) | 2019-05-28 | 2019-05-28 | Composite probiotic composition for improving breath, buccal tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110063374A CN110063374A (en) | 2019-07-30 |
| CN110063374B true CN110063374B (en) | 2021-07-09 |
Family
ID=67371745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910453030.0A Active CN110063374B (en) | 2019-05-28 | 2019-05-28 | Composite probiotic composition for improving breath, buccal tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110063374B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112293728A (en) * | 2020-07-13 | 2021-02-02 | 丽江美之源食品有限公司 | Fructus phyllanthi probiotic buccal tablet |
| CN114917176B (en) * | 2022-03-14 | 2023-06-13 | 江南大学 | Composite probiotics for improving halitosis |
| CN114712298A (en) * | 2022-03-28 | 2022-07-08 | 桂龙药业(安徽)有限公司 | Prebiotic and metabiotic composition for promoting oral health and application thereof |
| CN115212163A (en) * | 2022-06-20 | 2022-10-21 | 杭州国茶健康产业有限公司 | Natural herbal tea buccal tablet and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060062773A1 (en) * | 2004-09-21 | 2006-03-23 | The Procter & Gamble Company | Compositions for maintaining and restoring normal gastrointestinal flora |
| ES2818999T3 (en) * | 2017-11-03 | 2021-04-14 | Kyorin Ind Shenzhen Co Ltd | Chew toy for pets with oral care properties and toy preparation method |
| CN109528776A (en) * | 2018-06-08 | 2019-03-29 | 广东益可维健康科技有限公司 | A kind of compound probiotic lozenge of prophylactic treatment mouth disease and preparation method thereof |
-
2019
- 2019-05-28 CN CN201910453030.0A patent/CN110063374B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110063374A (en) | 2019-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110063374B (en) | Composite probiotic composition for improving breath, buccal tablet and preparation method thereof | |
| Lin et al. | Investiture of next generation probiotics on amelioration of diseases–Strains do matter | |
| Del Piano et al. | Probiotics: from research to consumer | |
| Chatterjee et al. | Probiotics in periodontal health and disease | |
| EP2848682B1 (en) | Isolation, identification and characterization of strains with probiotic activity from the faeces of babies fed exclusively with breast milk | |
| JP2018111711A (en) | Riboflavin, riboflavin phosphate, and physiologically acceptable salt thereof | |
| JP2019524636A (en) | Composition comprising lactic acid bacteria for the prevention and treatment of vaginosis and use thereof | |
| JP6796070B2 (en) | Foods and drinks containing indigestible components and hydrogen gas producing agents in the large intestine | |
| JPS615022A (en) | Ameliorant of enterobacterial flora | |
| KR102452792B1 (en) | Compositions and methods for reducing flatulence | |
| JPWO2002080946A1 (en) | Composition for prevention and / or treatment of oral disease | |
| Kumari et al. | Probiotics, prebiotics, and synbiotics: Current status and future uses for human health | |
| JP2010193841A (en) | Immunopotentiating fermented food from fructan-containing food | |
| Bao et al. | Structural characteristics and prebiotic effects of Semen coicis resistant starches (type 3) prepared by different methods | |
| Fissore et al. | A study of the effect of dietary fiber fractions obtained from artichoke (Cynara cardunculus L. var. scolymus) on the growth of intestinal bacteria associated with health | |
| TWI689585B (en) | Novel lactic acid strain and immune activating agent containing novel lactic acid strain | |
| Ai et al. | The specific use of alginate from Laminaria japonica by Bacteroides species determined its modulation of the Bacteroides community | |
| CN102618452B (en) | Preparation method, composition and application of lactobacillus salivarius and its metabolites | |
| Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
| JP2005013211A (en) | Lactobacillus-containing food composition | |
| JP2004051530A (en) | Intestinal flora-improving agent and food or drink containing the same | |
| JP2002065199A (en) | Method for producing fermented turmeric | |
| JP2011102250A (en) | Method for producing viable bacterial preparation | |
| CN101668534B (en) | Iga production promoter | |
| Yoshinaga et al. | Effects of Undaria pinnatifida (wakame) on the human intestinal environment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210918 Address after: Helingeer Shengle Economic Zone Hohhot city the Inner Mongolia Autonomous Region 011500 Patentee after: INNER MONGOLIA MENGNIU DAIRY (GROUP) Co.,Ltd. Patentee after: BEIJING SCITOP BIO-TECH Co.,Ltd. Address before: 101407 No.1-2, yard 31, yiniuhe Road, Yanqi Economic Development Zone, Huairou District, Beijing Patentee before: BEIJING SCITOP BIO-TECH Co.,Ltd. |
|
| TR01 | Transfer of patent right |